Spruce Biosciences Achieves Proof of Concept in Phase 2 Study of Tildacerfont in Congenital Adrenal Hyperplasia
– Tildacerfont demonstrates meaningful reduction in key disease biomarkers adrenocorticotropic hormone (ACTH), 17-hydroxyprogesterone (17-OHP) and androstenedione (A4)
– Well-tolerated and safe, tildacerfont holds potential as a treatment for patients with congenital adrenal hyperplasia, a rare endocrine disorder
Spruce Biosciences Announces Presentation of Positive Topline Data from Phase 2 Study of Tildacerfont (SPR001) in Congenital Adrenal Hyperplasia at the 2019 Annual Meeting of the Endocrine Society (ENDO)
Tildacerfont demonstrates potential to become the first approved therapy for congenital adrenal hyperplasia, a rare endocrine disorder
IN THE NEWS
Neurocrine Shines In Congenital Adrenal Hyperplasia, But Competitor Is Close
Spruce’s competing drug with same mechanism of action is also in Phase II, with data expected at the end of March.
Start-Up Spruce Repurposes Lilly Drug For Genetic Adrenal Condition
Emerging Company Profile: Spruce and Neurocrine are both testing CRF-R1 antagonists for the orphan disease congenital adrenal hyperplasia, with Phase II data coming soon.